Literature DB >> 13680167

Sepsis in neutropenia--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).

Xaver Schiel1, Holger Hebart, Winfried V Kern, Michael G Kiehl, Jens Peter Sölch, Stefan Wilhelm, Helmut Ostermann.   

Abstract

Patients developing fever in neutropenia are at high risk of infection-related complications. Their outcome is influenced by the degree of severity (sepsis, severe sepsis and septic shock). Sepsis describes clinical syndromes resulting from systemic inflammatory response. Diagnosis of sepsis is based on simple clinical criteria. Treatment of neutropenic patients with sepsis does not differ from sepsis treatment in non-neutropenic patients. A variety of treatment options have failed (e.g. anti-cytokine strategies, anti-endotoxin antibodies), however, in recent years successful targeted treatment, the use of activated protein C or the substitution of hydrocortisol has been shown to reduce mortality rates. The outcome of neutropenic sepsis is influenced by the underlying disease as well, however survival rates of neutropenic patients treated on the intensive care unit have improved during the past decade. This paper focuses on pathophysiology, diagnosis and treatment of sepsis. Evidence based medicine (EBM) criteria are used to grade treatment recommendations [50].

Entities:  

Mesh:

Year:  2003        PMID: 13680167     DOI: 10.1007/s00277-003-0770-6

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  6 in total

1.  Microbial etiology of febrile neutropenia.

Authors:  Mudshingkar Swati; Nataraj Gita; Baveja Sujata; Jijina Farah; Mehta Preeti
Journal:  Indian J Hematol Blood Transfus       Date:  2010-09-30       Impact factor: 0.900

2.  Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.

Authors:  Leon E Cosler; Adi Eldar-Lissai; Eva Culakova; Nicole M Kuderer; David Dale; Jeffrey Crawford; Gary H Lyman
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

3.  Documented and clinically suspected bacterial infection precipitating intensive care unit admission in patients with hematological malignancies: impact on outcome.

Authors:  Dominique D Benoit; Pieter O Depuydt; Renaat A Peleman; Fritz C Offner; Koenraad H Vandewoude; Dirk P Vogelaers; Stijn I Blot; Lucien A Noens; Francis A Colardyn; Johan M Decruyenaere
Journal:  Intensive Care Med       Date:  2005-03-22       Impact factor: 17.440

Review 4.  [Infection-related emergencies in oncology].

Authors:  X Schiel; C Rieger; H Ostermann
Journal:  Internist (Berl)       Date:  2005-01       Impact factor: 0.743

5.  How we treat febrile neutropenia in patients receiving cancer chemotherapy.

Authors:  Gary H Lyman; Kenneth V I Rolston
Journal:  J Oncol Pract       Date:  2010-05       Impact factor: 3.840

6.  Perioperative care in perforation peritonitis: Where do we stand?

Authors:  Rakesh Garg
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2013-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.